Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Show moreShow less
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Quality Score breakdown
Overall quality52/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability21
How much profit the company makes from its sales and capital
Quality Growth100
Are margins and returns getting better?
Cashflow6
Do the profits arrive as real cash?
Financial strength76
Debt, balance sheet and risk of trouble
Investment100
Does it invest with discipline instead of growing at any price?
Low Volatility0
How calm the share price moves, does not count
Price momentum84
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 11 officers or directors sold shares worth $63.3M and none bought.
SaleJulie RubinsteinPresident and COO23× since Mar 3, 2026: 1,270,194 shares, avg. $17.17$21.8MNov 6, 202610b5-1 plan
SaleSusan BobulskyChief Commercial Officer, MRD10× since Mar 11, 2026: 79,763 shares, avg. $17.52$1.4MOct 6, 2026
SaleFrancis LoChief People Officer12× since Dec 15, 2025: 675,773 shares, avg. $20.56$13.9MOct 1, 2026
SaleKatey Einterz OwenDirector9,615 shares at $26.00$249,990Aug 26, 2026
SaleRobert HershbergDirector2× since Dec 10, 2025: 53,632 shares, avg. $20.80$1.1MAug 18, 2026
SaleChad M RobinsCEO and Chairman, Director8× since Nov 10, 2025: 2,215,755 shares, avg. $17.96$39.8MAug 18, 2026
SalePeter M NeupertDirector124,690 shares at $25.15$3.1MAug 17, 2026
SaleHarlan S RobinsChief Scientific Officer10× since Nov 10, 2025: 1,589,299 shares, avg. $18.65$29.6MJul 21, 2026
SaleSharon BenzenoChief Commercial Ofc Imm Med4× since Nov 20, 2025: 847,911 shares, avg. $17.33$14.7MJun 29, 2026
SaleMichelle Renee GriffinDirector3× since Mar 3, 2026: 115,522 shares, avg. $17.31$2.0MJun 25, 2026
Plus 1 more entries from the last 12 months.
Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+54.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.0%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−155.3% (2020) → −20.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Adaptive Biotechnologies Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Profitability
Return on assets−11.6% · Bottom 25%
Net margin (12 months)−20.7% · Bottom 25%
Operating margin (12 months)−22.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)21.5% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Adaptive Biotechnologies Corp has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Adaptive Biotechnologies Corp (ADPT)?
Adaptive Biotechnologies Corp reported trailing-twelve-month revenue of about $308M (latest available figure, as of Nov 6, 2026).
How solid is the balance sheet of Adaptive Biotechnologies Corp (ADPT)?
Balance-sheet figures for Adaptive Biotechnologies Corp (as of Nov 6, 2026): return on equity −38.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
Which stocks are comparable to Adaptive Biotechnologies Corp?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Adaptive Biotechnologies Corp (ADPT)?
The closing price on Nov 6, 2026 was $27.98. We carry closing prices from our data provider, not a live tick.
Key figures of Adaptive Biotechnologies Corp
How large is the market capitalisation of Adaptive Biotechnologies Corp (ADPT)?
The market capitalisation of Adaptive Biotechnologies Corp is $4.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Adaptive Biotechnologies Corp (ADPT)?
The price-to-sales ratio of Adaptive Biotechnologies Corp is 13.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Adaptive Biotechnologies Corp (ADPT)?
Earnings per share at Adaptive Biotechnologies Corp are $−0.4100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Adaptive Biotechnologies Corp (ADPT)?
The net margin of Adaptive Biotechnologies Corp is −20.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Adaptive Biotechnologies Corp (ADPT)?
The return on equity (ROE) of Adaptive Biotechnologies Corp is −38.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Adaptive Biotechnologies Corp (ADPT)?
On an EBIT basis the return on assets of Adaptive Biotechnologies Corp is −24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Adaptive Biotechnologies Corp (ADPT)?
The operating margin of Adaptive Biotechnologies Corp is −22.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Adaptive Biotechnologies Corp (ADPT)?
Revenue at Adaptive Biotechnologies Corp is growing +21.5% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Adaptive Biotechnologies Corp (ADPT) generate?
The free cash flow of Adaptive Biotechnologies Corp is −$48.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Adaptive Biotechnologies Corp (ADPT) carry?
The net debt of Adaptive Biotechnologies Corp is $210M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Adaptive Biotechnologies Corp in the live analysis
One click puts Adaptive Biotechnologies Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026